<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=2">
<meta name="theme-color" content="#222">
<meta name="generator" content="Hexo 5.2.0">
  <link rel="apple-touch-icon" sizes="180x180" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico">
  <link rel="icon" type="image/png" sizes="32x32" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico">
  <link rel="icon" type="image/png" sizes="16x16" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico">
  <link rel="mask-icon" href="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/Logo2.ico" color="#222">

<link rel="stylesheet" href="/css/main.css">

<link rel="stylesheet" href="//fonts.googleapis.com/css?family=Lato:300,300italic,400,400italic,700,700italic|14px:300,300italic,400,400italic,700,700italic&display=swap&subset=latin,latin-ext">
<link rel="stylesheet" href="/lib/font-awesome/css/all.min.css">
  <link rel="stylesheet" href="//cdn.jsdelivr.net/gh/fancyapps/fancybox@3/dist/jquery.fancybox.min.css">
  <link rel="stylesheet" href="/lib/pace/pace-theme-corner-indicator.min.css">
  <script src="/lib/pace/pace.min.js"></script>

<script id="hexo-configurations">
    var NexT = window.NexT || {};
    var CONFIG = {"hostname":"zhenyumi.github.io","root":"/","scheme":"Gemini","version":"7.8.0","exturl":false,"sidebar":{"position":"left","display":"post","padding":18,"offset":12,"onmobile":false},"copycode":{"enable":true,"show_result":true,"style":"mac"},"back2top":{"enable":true,"sidebar":false,"scrollpercent":true},"bookmark":{"enable":true,"color":"#000000","save":"auto"},"fancybox":{"enable":true,"caption":false},"mediumzoom":false,"lazyload":true,"pangu":true,"comments":{"style":"valine","active":null,"storage":true,"lazyload":false,"nav":null},"algolia":{"hits":{"per_page":10},"labels":{"input_placeholder":"Search for Posts","hits_empty":"We didn't find any results for the search: ${query}","hits_stats":"${hits} results found in ${time} ms"}},"localsearch":{"enable":true,"trigger":"auto","top_n_per_article":1,"unescape":false,"preload":false},"motion":{"enable":true,"async":true,"transition":{"post_block":"slideDownBigIn","post_header":"slideDownIn","post_body":"slideDownIn","coll_header":"slideLeftIn","sidebar":"slideUpIn"}},"path":"./public/search.xml"};
  </script>

  <meta name="description" content="Antiseizures And Drugs for Parkinson’s disease">
<meta property="og:type" content="article">
<meta property="og:title" content="L13 Antiseizures And Drugs for Parkinson’s">
<meta property="og:url" content="https://zhenyumi.github.io/posts/bdf8ab92.html">
<meta property="og:site_name" content="鹘横海">
<meta property="og:description" content="Antiseizures And Drugs for Parkinson’s disease">
<meta property="og:locale" content="zh_CN">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524191726150.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524191740348.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192210074.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192502806.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192516550.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192835859.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192851537.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524193718795.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524193748054.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524193951705.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194004958.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194012884.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194231375.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194507873.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194509918.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194836906.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194906010.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194909909.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524195906377.png">
<meta property="article:published_time" content="2021-06-01T07:47:12.000Z">
<meta property="article:modified_time" content="2021-06-01T07:47:12.000Z">
<meta property="article:author" content="向海">
<meta property="article:tag" content="Molecular Pharmacology">
<meta name="twitter:card" content="summary">
<meta name="twitter:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524191726150.png">

<link rel="canonical" href="https://zhenyumi.github.io/posts/bdf8ab92.html">


<script id="page-configurations">
  // https://hexo.io/docs/variables.html
  CONFIG.page = {
    sidebar: "",
    isHome : false,
    isPost : true,
    lang   : 'zh-CN'
  };
</script>

  <title>L13 Antiseizures And Drugs for Parkinson’s | 鹘横海</title>
  


  <script data-pjax>
    var _hmt = _hmt || [];
    (function() {
      var hm = document.createElement("script");
      hm.src = "https://hm.baidu.com/hm.js?aa95e0eb65e5b58f6500e4de221c0f67";
      var s = document.getElementsByTagName("script")[0];
      s.parentNode.insertBefore(hm, s);
    })();
  </script>




  <noscript>
  <style>
  .use-motion .brand,
  .use-motion .menu-item,
  .sidebar-inner,
  .use-motion .post-block,
  .use-motion .pagination,
  .use-motion .comments,
  .use-motion .post-header,
  .use-motion .post-body,
  .use-motion .collection-header { opacity: initial; }

  .use-motion .site-title,
  .use-motion .site-subtitle {
    opacity: initial;
    top: initial;
  }

  .use-motion .logo-line-before i { left: initial; }
  .use-motion .logo-line-after i { right: initial; }
  </style>
</noscript>

</head>

<body itemscope itemtype="http://schema.org/WebPage">
  <div class="container use-motion">
    <div class="headband"></div>

    <header class="header" itemscope itemtype="http://schema.org/WPHeader">
      <div class="header-inner"><div class="site-brand-container">
  <div class="site-nav-toggle">
    <div class="toggle" aria-label="切换导航栏">
      <span class="toggle-line toggle-line-first"></span>
      <span class="toggle-line toggle-line-middle"></span>
      <span class="toggle-line toggle-line-last"></span>
    </div>
  </div>

  <div class="site-meta">

    <a href="/" class="brand" rel="start">
      <span class="logo-line-before"><i></i></span>
      <h1 class="site-title">鹘横海</h1>
      <span class="logo-line-after"><i></i></span>
    </a>
      <p class="site-subtitle" itemprop="description">Hope tomorrow is still shining.  Today is another day.</p>
  </div>

  <div class="site-nav-right">
    <div class="toggle popup-trigger">
        <i class="fa fa-search fa-fw fa-lg"></i>
    </div>
  </div>
</div>




<nav class="site-nav">
  <ul id="menu" class="main-menu menu">
        <li class="menu-item menu-item-home">

    <a href="/" rel="section"><i class="fa fa-home fa-fw"></i>首页</a>

  </li>
        <li class="menu-item menu-item-about">

    <a href="/about/" rel="section"><i class="fa fa-user fa-fw"></i>关于</a>

  </li>
        <li class="menu-item menu-item-tags">

    <a href="/tags/" rel="section"><i class="fa fa-tags fa-fw"></i>标签<span class="badge">23</span></a>

  </li>
        <li class="menu-item menu-item-categories">

    <a href="/categories/" rel="section"><i class="fa fa-th fa-fw"></i>分类<span class="badge">23</span></a>

  </li>
        <li class="menu-item menu-item-archives">

    <a href="/archives/" rel="section"><i class="fa fa-archive fa-fw"></i>归档<span class="badge">187</span></a>

  </li>
        <li class="menu-item menu-item-留言板">

    <a href="/%E7%95%99%E8%A8%80%E6%9D%BF/" rel="section"><i class="fas fa-chalkboard-teacher fa-fw"></i>留言板</a>

  </li>
      <li class="menu-item menu-item-search">
        <a role="button" class="popup-trigger"><i class="fa fa-search fa-fw"></i>搜索
        </a>
      </li>
  </ul>
</nav>



  <div class="search-pop-overlay">
    <div class="popup search-popup">
        <div class="search-header">
  <span class="search-icon">
    <i class="fa fa-search"></i>
  </span>
  <div class="search-input-container">
    <input autocomplete="off" autocapitalize="off"
           placeholder="搜索..." spellcheck="false"
           type="search" class="search-input">
  </div>
  <span class="popup-btn-close">
    <i class="fa fa-times-circle"></i>
  </span>
</div>
<div id="search-result">
  <div id="no-result">
    <i class="fa fa-spinner fa-pulse fa-5x fa-fw"></i>
  </div>
</div>

    </div>
  </div>

</div>
    </header>

    
  <div class="back-to-top">
    <i class="fa fa-arrow-up"></i>
    <span>0%</span>
  </div>
  <div class="reading-progress-bar"></div>
  <a role="button" class="book-mark-link book-mark-link-fixed"></a>


    <main class="main">
      <div class="main-inner">
        <div class="content-wrap">
          

          <div class="content post posts-expand">
            

    
  
  
  <article itemscope itemtype="http://schema.org/Article" class="post-block" lang="zh-CN">
    <link itemprop="mainEntityOfPage" href="https://zhenyumi.github.io/posts/bdf8ab92.html">

    <span hidden itemprop="author" itemscope itemtype="http://schema.org/Person">
      <meta itemprop="image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/pixil-frame-0.png">
      <meta itemprop="name" content="向海">
      <meta itemprop="description" content="希望能活的久一点">
    </span>

    <span hidden itemprop="publisher" itemscope itemtype="http://schema.org/Organization">
      <meta itemprop="name" content="鹘横海">
    </span>
      <header class="post-header">
        <h1 class="post-title" itemprop="name headline">
          L13 Antiseizures And Drugs for Parkinson’s
        </h1>

        <div class="post-meta">
            <span class="post-meta-item">
              <span class="post-meta-item-icon">
                <i class="far fa-calendar"></i>
              </span>
              <span class="post-meta-item-text">发表于</span>

              <time title="创建时间：2021-06-01 15:47:12" itemprop="dateCreated datePublished" datetime="2021-06-01T15:47:12+08:00">2021-06-01</time>
            </span>
            <span class="post-meta-item">
              <span class="post-meta-item-icon">
                <i class="far fa-folder"></i>
              </span>
              <span class="post-meta-item-text">分类于</span>
                <span itemprop="about" itemscope itemtype="http://schema.org/Thing">
                  <a href="/categories/Academic-Notebook/" itemprop="url" rel="index"><span itemprop="name">Academic Notebook</span></a>
                </span>
                  ，
                <span itemprop="about" itemscope itemtype="http://schema.org/Thing">
                  <a href="/categories/Academic-Notebook/Molecular-Pharmacology/" itemprop="url" rel="index"><span itemprop="name">Molecular Pharmacology</span></a>
                </span>
            </span>

          
            <span class="post-meta-item" title="阅读次数" id="busuanzi_container_page_pv" style="display: none;">
              <span class="post-meta-item-icon">
                <i class="fa fa-eye"></i>
              </span>
              <span class="post-meta-item-text">阅读次数：</span>
              <span id="busuanzi_value_page_pv"></span>
            </span>
  
  <span class="post-meta-item">
    
      <span class="post-meta-item-icon">
        <i class="far fa-comment"></i>
      </span>
      <span class="post-meta-item-text">Valine：</span>
    
    <a title="valine" href="/posts/bdf8ab92.html#valine-comments" itemprop="discussionUrl">
      <span class="post-comments-count valine-comment-count" data-xid="/posts/bdf8ab92.html" itemprop="commentCount"></span>
    </a>
  </span>
  
  <br>
            <span class="post-meta-item" title="本文字数">
              <span class="post-meta-item-icon">
                <i class="far fa-file-word"></i>
              </span>
                <span class="post-meta-item-text">本文字数：</span>
              <span>13k</span>
            </span>

        </div>
      </header>

    
    
    
    <div class="post-body" itemprop="articleBody">

      
        <h1 id="一-introduction"><a class="markdownIt-Anchor" href="#一-introduction"></a> 一、Introduction</h1>
<p>Epilepsy(癫痫)is a heterogeneous symptom complex—a chronic disorder characterized by recurrent seizures.</p>
<p>Seizures (癫痫发作) are finite episodes of brain dysfunction resulting from abnormal discharge of cerebral neurons: Disruption of the depolarization and repolarization mechanisms</p>
<ul>
<li>Approximately 1% of the world’s population has epilepsy, the 3rd most common neurologic disorder after dementia and stroke.</li>
<li>The antiseizure drugs described in this chapter are also used in patients with seizures occurring as part of an acute illness such as <strong>meningitis</strong>. Seizures are occasionally caused by an acute underlying toxic or metabolic disorder, in which case appropriate therapy should be directed toward the specific abnormality, eg, <strong>hypocalcemia</strong> (low calcium in serum).</li>
</ul>
<p>In most cases of epilepsy, however, the choice of medication depends on the empiric seizure classification.</p>
<h2 id="nature-of-epilepsy"><a class="markdownIt-Anchor" href="#nature-of-epilepsy"></a> Nature of Epilepsy</h2>
<p>• Seizures may be partial or generalised depending on the <u>location and spread</u> of the abnormal neuronal discharge. The attack may involve mainly <strong>motor</strong>, <strong>sensory</strong> or behavioural phenomena. Unconsciousness occurs when the <u>reticular formation</u> is involved.</p>
<p><strong>reticular formation</strong>:网状结构（英语： reticular formation）是脑部涉及到例如觉醒 /睡眠循环等动作的部分</p>
<h2 id="types-of-epilepsy"><a class="markdownIt-Anchor" href="#types-of-epilepsy"></a> Types of Epilepsy</h2>
<p>Two major categories, namely partial and generalised seizures; there is some overlap and many varieties of each.</p>
<p><strong>Generalised seizures</strong> 全身性癫痫</p>
<ul>
<li>Involve the whole brain, including the reticular system, thus producing <u>abnormal electrical activity</u> throughout both hemispheres. Immediate loss of consciousness.</li>
</ul>
<p><strong>Partial (Focal) seizures</strong> 部分(局灶性)癫痫发作</p>
<ul>
<li>The discharge begins locally, and often remains localised.</li>
<li>Produce relatively simple symptoms without loss of consciousness.</li>
</ul>
<h2 id="seizure-classification"><a class="markdownIt-Anchor" href="#seizure-classification"></a> Seizure Classification</h2>
<h3 id="1-generalized-seizures"><a class="markdownIt-Anchor" href="#1-generalized-seizures"></a> 1. Generalized Seizures</h3>
<p>Generalized seizures are those in which there is no evidence of localized onset. The group is quite heterogeneous.</p>
<ol>
<li><strong>Generalized tonic-clonic seizures (全身性强直阵挛性癫痫)</strong> are the most dramatic of all epileptic seizures and are characterized by <u>tonic rigidity (muscle stiffness)</u> of all extremities, followed in 15–30 seconds by <u>a tremor (muscle contraction)</u> that is actually an interruption of the tonus by relaxation</li>
<li><strong>The absence seizure (失神发作)</strong> is characterized by <u>both sudden onset and abrupt cessation</u>. Its duration is usually less than 10 seconds and rarely more than 45 seconds. Consciousness is altered. Absence attacks begin in childhood or adolescence and may occur up to hundreds of times a day.</li>
<li><strong>Atonic seizures (无张力癫痫)</strong> are those in which the patient has sudden loss of postural tone. If standing, the patient falls suddenly to the floor and may be injured</li>
</ol>
<h3 id="2-partial-seizures"><a class="markdownIt-Anchor" href="#2-partial-seizures"></a> 2. Partial Seizures</h3>
<p><u>A localized onset</u> of the attack can be ascertained, either by clinical observation or by electroencephalographic recording; the attack begins in a specific locus in the brain.</p>
<ol>
<li><strong>Simple partial seizure</strong>, characterized by <u>minimal spread</u> of the abnormal discharge such that normal consciousness and awareness are preserved. lasting 60–90 seconds; residual weakness may last for 15–30 minutes after the attack</li>
<li><strong>The complex partial seizure</strong> also has a localized onset, but the discharge becomes <u>more widespread (usually bilateral)</u> and almost always involves the limbic system. Clinically, the patient may have a brief warning followed by an alteration of consciousness during which some patients stare and others stagger or even fall. After 30–120 seconds, the patient makes a gradual recovery to normal consciousness but may feel tired or ill for several hours after the attack.</li>
<li><strong>The secondarily generalized attack (继发性全身性发作)</strong>, in which a partial seizure immediately precedes a generalized tonic-clonic seizure</li>
</ol>
<h1 id="二-basic-pharmacology-of-antiseizure-drugs"><a class="markdownIt-Anchor" href="#二-basic-pharmacology-of-antiseizure-drugs"></a> 二、Basic Pharmacology of Antiseizure Drugs</h1>
<h2 id="drug-mechanisms"><a class="markdownIt-Anchor" href="#drug-mechanisms"></a> Drug mechanisms</h2>
<h3 id="1-inhibition-of-excitatory-synapse"><a class="markdownIt-Anchor" href="#1-inhibition-of-excitatory-synapse"></a> 1. Inhibition of Excitatory Synapse</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524191726150.png" alt="image-20210524191726150" style="zoom:100%;" />
### 2. Activation of Inhibitory Synapse (GABA)
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524191740348.png" alt="image-20210524191740348" style="zoom:100%;" />
### 3. Inhibition of sodium channel function
<p>phenytoin, carbamazepine, valproic acid, lamotrigine</p>
<h3 id="4-enhancement-of-gaba-actions"><a class="markdownIt-Anchor" href="#4-enhancement-of-gaba-actions"></a> 4. Enhancement of GABA actions</h3>
<ul>
<li>Increase GABA actions at receptor (benzodiazepines, phenobarbital)</li>
<li>vigabatrin inhibits GABA transaminase</li>
<li>Tiagabin blocks GABA uptake</li>
</ul>
<h3 id="5-inhibition-of-calcium-pq-type-channels"><a class="markdownIt-Anchor" href="#5-inhibition-of-calcium-pq-type-channels"></a> 5. Inhibition of Calcium P/Q-type channels</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192210074.png" alt="image-20210524192210074" style="zoom:100%;" />
Gabapentin, pregabalin
<h2 id="drugs-used-in-partial-seizures-generalized-tonic-clonic-seizures"><a class="markdownIt-Anchor" href="#drugs-used-in-partial-seizures-generalized-tonic-clonic-seizures"></a> Drugs Used in Partial Seizures &amp; Generalized Tonic-Clonic Seizures</h2>
<p>The classic major drugs for partial and generalized tonic-clonic seizures are <strong>phenytoin</strong> (and congeners), <strong>carbamazepine</strong>, <strong>valproate</strong>, and the <strong>barbiturates</strong>.</p>
<p>The availability of newer drugs—<strong>lamotrigine, levetiracetam, gabapentin, oxcarbazepine, pregabalin, topiramate, vigabatrin, and zonisamide</strong> is altering clinical practice in countries where these compounds are available</p>
<h3 id="1-phenytoin"><a class="markdownIt-Anchor" href="#1-phenytoin"></a> 1. Phenytoin</h3>
<p>Phenytoin is the <strong>oldest</strong> nonsedative antiseizure drug.</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192502806.png" alt="image-20210524192502806" style="zoom:100%;" />
**Mechanism of Action**
<ul>
<li>It is a use-dependent effect on Na<sup>+</sup> conductance, arising from preferential <u>binding to—and prolongation of—the inactivated state of the Na<sup>+</sup> channel.</u></li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192516550.png" alt="image-20210524192516550" style="zoom:100%;" />
**Clinical Use**
<ul>
<li><u>Phenytoin is effective against partial seizures and generalized tonic-clonic seizures</u>. In the latter, it appears to be effective against attacks that are either primary or secondary to another seizure type.</li>
</ul>
<p><strong>Pharmacokinetics</strong></p>
<ul>
<li>Absorption of phenytoin sodium from the gastrointestinal tract is nearly complete in most patients. Intramuscular injection is not recommended for phenytoin.</li>
<li><u>Phenytoin is highly bound to plasma proteins</u>. Drug concentration in cerebrospinal fluid is proportionate to the free plasma level. <u>Phenytoin accumulates in brain, liver, muscle, and fat.</u></li>
</ul>
<p><strong>Drug Interactions &amp; Interference with Laboratory Tests</strong></p>
<ul>
<li>Since phenytoin is 90% bound to plasma proteins, other highly bound drugs, such as phenylbutazone and sulfonamides, can displace phenytoin from its binding site. In theory, such displacement may cause a transient increase in free drug</li>
<li>A decrease in protein binding—eg, from <strong>hypoalbuminemia</strong>—results in a decrease in the total plasma concentration of drug but not the free concentration. <strong>Intoxication</strong> may occur if efforts are made to maintain total drug levels in the therapeutic range by increasing the dose.</li>
<li>Phenytoin has been shown to induce microsomal enzymes responsible for the metabolism of a number of drugs. Autostimulation of its own metabolism, however, appears to be insignificant.</li>
</ul>
<h3 id="2-carbamazepine"><a class="markdownIt-Anchor" href="#2-carbamazepine"></a> 2. Carbamazepine</h3>
<p>Drug for bipolar depression. It was initially marketed for the treatment of trigeminal neuralgia but has proved useful for epilepsy as well.</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192835859.png" alt="image-20210524192835859" style="zoom: 50%;" />
<p><strong>Mechanism of Action</strong></p>
<ul>
<li>blocks sodium channels</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524192851537.png" alt="image-20210524192851537" style="zoom:100%;" />
### 3. Phenobarbital 
<p><strong>The oldest of the currently available antiseizure drugs</strong></p>
<p><strong>Mechanism of Action</strong></p>
<ul>
<li>Enhancement of inhibitory process</li>
<li>Diminution of excitatory transmission</li>
</ul>
<p><strong>Clinical Use</strong></p>
<ul>
<li>partial seizures, generalized tonic-clonic seizures</li>
</ul>
<p><strong>Therapeutic Levels, &amp; Dosage</strong></p>
<ul>
<li>From 10 mcg/mL to 40 mcg/mL</li>
<li>Documentation of effectiveness is best in febrile seizures, and levels below 15mcg/mL appear ineffective for prevention of febrile seizure recurrence.</li>
<li>The upper end of the therapeutic range is more difficult to define because many patients appear to tolerate chronic levels above 40 mcg/mL</li>
</ul>
<h3 id="4-valproic-acid-sodium-valproate"><a class="markdownIt-Anchor" href="#4-valproic-acid-sodium-valproate"></a> 4. Valproic Acid &amp; Sodium Valproate</h3>
<p><strong>Mechanism of Action</strong></p>
<ul>
<li>Effect on Na<sup>+</sup> currents.</li>
<li>Blockade of NMDA receptor-mediated excitation</li>
<li>Effects on GABA
<ul>
<li>To increase levels of GABA in the brain after administration of valproate, by facilitating glutamic acid decarboxylase (GAD), the enzyme responsible for GABA synthesis, has been described. An inhibitory effect on the GABA transporter GAT-1 may contribute.</li>
<li>At very high concentrations, valproate inhibits GABA transaminase in the brain, thus blocking degradation of GABA.</li>
</ul>
</li>
</ul>
<p><strong>Drug Interactions</strong></p>
<ul>
<li>Valproate displaces phenytoin from plasma proteins. In addition to binding interactions, valproate inhibits the metabolism of several drugs, including phenobarbital, phenytoin, and carbamazepine, leading to higher steady-state concentrations of these agents.</li>
</ul>
<h1 id="三-degenerative-diseases-of-the-nervous-system"><a class="markdownIt-Anchor" href="#三-degenerative-diseases-of-the-nervous-system"></a> 三、Degenerative Diseases of the Nervous System</h1>
<p>Chronic neurological conditions associated with progressive loss of neurons.</p>
<ul>
<li>evidence of inflammation?</li>
<li>evidence of cellular necrosis?</li>
</ul>
<p>Examples:</p>
<ul>
<li>Parkinson’s disease.</li>
<li>Alzheimer’s disease.</li>
<li>Motor neuron disease (ALS)</li>
</ul>
<h2 id="parkinsons-disease"><a class="markdownIt-Anchor" href="#parkinsons-disease"></a> Parkinson’s disease</h2>
<h3 id="1-introduction"><a class="markdownIt-Anchor" href="#1-introduction"></a> 1. Introduction</h3>
<p>2<sup>nd</sup> most common neurodegenerative disease</p>
<ul>
<li>Mean onset = 57 years of age.</li>
<li>Affects 1-2% of population over 60 years of age.</li>
</ul>
<p>Etiology is unknown</p>
<p>Disease progression is highly variable</p>
<p>Can be early onset in some cases.</p>
<h3 id="2-parkinsonism"><a class="markdownIt-Anchor" href="#2-parkinsonism"></a> 2. Parkinsonism</h3>
<p><strong>Tremors</strong> – hands and head develop involuntary movements when at rest; pin‐rolling sign (finger and thumb)</p>
<p><strong>Muscle rigidity</strong> – arthritis‐like stiffness, difficulty in bending or moving limbs; poker face</p>
<p><strong>Bradykinesia</strong> (运动迟缓) – problems chewing, swallowing or speaking; difficulty in initiating movements and controlling fine movements; walking becomes difficult (shuffle feet)</p>
<p><strong>Postural instability</strong> (姿势不稳) – humped over appearance, prone to falls</p>
<h3 id="3-the-substantia-nigra-黑质-in-parkinsons-disease"><a class="markdownIt-Anchor" href="#3-the-substantia-nigra-黑质-in-parkinsons-disease"></a> 3. The Substantia Nigra (黑质) in Parkinson’s Disease</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524193718795.png" alt="image-20210524193718795" style="zoom:100%;" />
+ Symptoms related to selective loss of pigmental neurons in the midbrain. Substantia nigra pars compacta – Dopaminergic neurotransmission to caudate nuclei (i.e., striatum) and putamen.
<h3 id="4-drug-treatment-of-parkinsons-disease"><a class="markdownIt-Anchor" href="#4-drug-treatment-of-parkinsons-disease"></a> 4. Drug Treatment of Parkinson’s Disease</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524193748054.png" alt="image-20210524193748054" style="zoom:100%;" />
### 5. Pathogenesis
<p><strong>Familial PD</strong>: first mutation discovered was in gene that coded for synuclein; several further gene loci discovered.</p>
<p><strong>Sporadic PD</strong>: no significant gene association as opposed to AD with the apolipoprotein E association</p>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524193951705.png" alt="image-20210524193951705" style="zoom:100%;" />
**Lewy Bodies – H&E Section**
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194004958.png" alt="image-20210524194004958" style="zoom:100%;" />
**Lewy Bodies –** **Immunoperoxidase staining**
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194012884.png" alt="image-20210524194012884" style="zoom:100%;" />
α-synuclein – abnormally deposited in the CNS in Parkinson’s Disease, leading to the formation of Lewy bodies (the pathological hallmark of PD)
<p>Reactive protofibrils of α-synuclein increased by catecholamines (i.e., dopamine).</p>
<ul>
<li>Cytoplasmic oxidation of dopamine -&gt; hydroxydopamine leads to formation of Lewy bodies causing dopaminergic cell death</li>
</ul>
<h3 id="6-mptp-and-dopaminergic-neurons"><a class="markdownIt-Anchor" href="#6-mptp-and-dopaminergic-neurons"></a> 6. MPTP and Dopaminergic Neurons</h3>
<p>MPTP – <u>induces oxidative damage</u> to dopaminergic neurons.</p>
<ul>
<li>Effect identified in 1976 due to incorrect synthesis of MPPP, an analogue of pethidine (Demerol – opioid analgesic).</li>
<li>Symptoms of Parkinson’s disease observed within 3 days.</li>
</ul>
<p>Effect on dopaminergic neurons is indirect.</p>
<ul>
<li>MPTP itself is not a neurotoxin</li>
<li>Enzymatically converted (via MAO-B (Monoamine oxidases B)) in the CNS to MPP+, which selectively targets dopaminergic neurons in the substantia nigra</li>
<li>MPP+ high-affinity substrate for dopamine reuptake transporters localized to the pre-synaptic membrane of neurons in the substantia nigra.</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194231375.png" alt="image-20210524194231375" style="zoom:100%;" />
### 7. Oxidative stress and Parkinson’s Disease
<p>Dopamine metabolism results in reactive oxygen species (oxidative deamination of dopamine by MAO -&gt; H2O2).</p>
<p>Glutathione (primary CNS antioxidant) levels are depressed in Parkinson’s disease.</p>
<ul>
<li>Renders neurons more susceptible to ROS toxicity</li>
<li>Observed in workers exposed to insecticides/pesticides.</li>
</ul>
<p>Coenzyme Q10 study: 1200 mg/day may slow progression.</p>
<h3 id="8-summary"><a class="markdownIt-Anchor" href="#8-summary"></a> 8. Summary</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194507873.png" alt="image-20210524194507873" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194509918.png" alt="image-20210524194509918" style="zoom:100%;" />
## Pharmacological Treatment of Parkinson’s Disease
<p>Goals:</p>
<ul>
<li>Primary = restore dopamine receptor function</li>
<li>Secondary = inhibition of muscarinic cholinergic receptors</li>
</ul>
<p>Several types of drugs:</p>
<ul>
<li>Levodopa</li>
<li>Dopamine Receptor Agonists</li>
<li>Monoamine Oxidase Inhibitors (MAOIs).</li>
<li>Catechol-O-Methyltransferase (COMT) inhibitors.</li>
<li>Muscarinic Cholinergic Receptor Antagonists.</li>
<li>Amantidine</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194836906.png" alt="image-20210524194836906" style="zoom:100%;" />
Other Drugs
<ul>
<li>Dopamine Receptor Agonists</li>
<li>Enzyme inhibitors</li>
<li>Dopamine Facillitators</li>
</ul>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194906010.png" alt="image-20210524194906010" style="zoom:100%;" />
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524194909909.png" alt="image-20210524194909909" style="zoom:100%;" />
### 1. Levodopa
<p>Prodrug – immediate metabolic precursor of dopamine.</p>
<ul>
<li><u>Levodopa can cross the blood-brain barrier</u> while dopamine cannot.</li>
<li>CNS – enzymatically converted to dopamine by L-aromatic amino acid decarboxylase.</li>
</ul>
<p>1-3% of Levodopa actually enters the brain.</p>
<ul>
<li>Primarily due to extracerebral metabolism</li>
<li>Extracerebral metabolism can be reduced by administering a non-BBB permeating peripheral L-aromatic amino acid decarboxylase inhibitor.</li>
</ul>
<p>Sinemet® = levodopa + carbidopa</p>
<p><strong>Mechanism of Action</strong>: restoration of synaptic concentrations of dopamine.</p>
<ul>
<li><u>Activation of post-synaptic D2 receptors</u> = inhibit adenylyl cyclase = promote voluntary movement via indirect pathway.</li>
</ul>
<p>Therapeutic Effectiveness</p>
<ul>
<li><strong>Best results obtained in first few years of treatment.</strong></li>
<li>80% of patients show marked initial improvement (primarily in terms of resolution of muscle rigidity and bradykinesia)</li>
<li>20% show virtually normal motor function.</li>
<li>Over time, levodopa therapy becomes less effective
<ul>
<li>Progressive loss of dopaminergic neurons</li>
<li>Downregulation of D1/D2 receptors on post-synaptic terminals.</li>
<li>Some patients require reduced doses of levodopa to prevent side effects</li>
</ul>
</li>
</ul>
<h3 id="2-dopamine-receptor-agonists"><a class="markdownIt-Anchor" href="#2-dopamine-receptor-agonists"></a> 2. Dopamine Receptor Agonists</h3>
<p><strong>Ropinirole</strong> (Requip®) – D2 receptor agonist.</p>
<ul>
<li>Effective as monotherapy in patients with mild disease.</li>
</ul>
<p><strong>Apomorphine</strong> – potent D1/D2 agonist</p>
<ul>
<li>Given via subcutaneous injection to provide temporary relief of “off” periods of akinesia.</li>
<li>Short period of effectiveness ( ~ 2 h).</li>
<li>Associated with several side effects (i.e., dyskinesias, drowsiness, sweating, hypotension).</li>
</ul>
<h3 id="3-monoamine-oxidase-inhibitors-maois"><a class="markdownIt-Anchor" href="#3-monoamine-oxidase-inhibitors-maois"></a> 3. Monoamine Oxidase Inhibitors (MAOIs)</h3>
<p>Two types of MAO have been characterized.</p>
<ul>
<li>MAO-A – primarily metabolizes NE and 5-HT.</li>
<li><strong>MAO-B – primarily metabolizes dopamine</strong></li>
</ul>
<p>Selegiline (Eldepryl®)</p>
<ul>
<li>Selective, irreversible inhibitors of MAO-B.</li>
</ul>
<h3 id="4-selegiline-mao-b-inhibitor"><a class="markdownIt-Anchor" href="#4-selegiline-mao-b-inhibitor"></a> 4. Selegiline – MAO-B Inhibitor</h3>
<p>Therapeutic Effectiveness</p>
<ul>
<li>Effective in early Parkinson’s disease (as monotherapy or in combination with levodopa)</li>
<li>Enables reduction in levodopa dose or may smooth the “on-off” fluctuations associated with levodopa</li>
<li>Metabolite = Desmethylselegiline – neuroprotective.</li>
</ul>
<p>Adverse Effects</p>
<ul>
<li>Selectivity for brain MAO-B makes selegiline less likely to produce ADRs involving peripheral tyramine (i.e., wine, cheese, and chopped liver syndrome).
<ul>
<li>Tyramine = catecholamine releasing agent</li>
</ul>
</li>
<li>Blocks MAO-A at high doses.
<ul>
<li>Hypertensive crisis due to peripheral accumulation of NE.</li>
</ul>
</li>
<li>Fatal hyperthermia – may occur when administered in conjunction with meperidine, cocaine, or fluoxetine.</li>
</ul>
<h3 id="5-catechol-o-methyltransferase-comt-inhibitors"><a class="markdownIt-Anchor" href="#5-catechol-o-methyltransferase-comt-inhibitors"></a> 5. Catechol-O-Methyltransferase (COMT) Inhibitors</h3>
<p>Inhibition of L-aromatic amino acid decarboxylase is associated with compensatory activation of COMT.</p>
<ul>
<li>Increased plasma levels of 3-OMD = poor response to levodopa (competition for active transporter in the gut and at the BBB?)</li>
</ul>
<p>Adjunctive therapy in patients treated with levodopa.</p>
<h4 id="entacapone"><a class="markdownIt-Anchor" href="#entacapone"></a> Entacapone</h4>
<p>Selective COMT inhibitors – diminish peripheral metabolism of levodopa.</p>
<p>May also reduce “on-off” fluctuations</p>
<p>Adverse Effects:</p>
<ul>
<li>Related to increased plasma concentrations of levodopa.</li>
<li>Include dyskinesias, nausea, and confusion.</li>
<li>Other side effects: diarrhea, abdominal pain, orthostatic hypotension, sleep disorders, orange urine discoloration.</li>
<li>Tolcapone – potentially hepatotoxic.</li>
</ul>
<h3 id="6-acetylcholineblocking-drugs"><a class="markdownIt-Anchor" href="#6-acetylcholineblocking-drugs"></a> 6. Acetylcholine‐Blocking Drugs</h3>
<img data-src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524195906377.png" alt="image-20210524195906377" style="zoom:100%;" />
### 7. Muscarinic Cholinergic Receptor Antagonists
<p>Muscarinic Receptors – localized to striatal neurons.</p>
<ul>
<li>Mediate cholinergic tremor</li>
<li>May cause presynaptic inhibition of dopamine release</li>
</ul>
<p>Trihexyphenidyl (Artane®) and Benztropine (Cogentin®)</p>
<ul>
<li>Therapeutic Effectiveness
<ul>
<li>Useful in patients administered neuroleptics as anti-dopaminergic properties of these drugs antagonize effects of levodopa</li>
<li>Improve muscle rigidity and tremor but have little effect on bradykinesia.</li>
</ul>
</li>
<li>Adverse Effects
<ul>
<li>Characterized as “<strong>atropine</strong>-like” = dry mouth, inability to sweat, impaired vision, urinary retention, constipation, drowsiness, confusion.</li>
</ul>
</li>
</ul>
<h3 id="8-amantidine-symmetrel-dopamine-facillitator"><a class="markdownIt-Anchor" href="#8-amantidine-symmetrel-dopamine-facillitator"></a> 8. Amantidine (Symmetrel®) Dopamine facillitator</h3>
<p>Antiviral drug with anti-Parkinsonian properties.</p>
<p>Mechanism of action is unclear</p>
<ul>
<li>Potentiates dopaminergic function by modifying synthesis, release, or reuptake of dopamine. Act on NMDA receptor</li>
</ul>
<p>Therapeutic Effectiveness</p>
<ul>
<li>Less effective than levodopa</li>
<li>Therapeutic benefits are short-lived.</li>
</ul>
<p>Adverse Effects</p>
<ul>
<li>Primarily CNS = restlessness, depression, irritability, insomnia, agitation, excitement, hallucinations, confusion</li>
<li>Overdoses = acute toxic psychosis</li>
<li>Others = headache, edema, postural hypotension, heart failure, GI disturbances.</li>
</ul>

    </div>

    
    
    

      <footer class="post-footer">
          
          <div class="post-tags">
              <a href="/tags/Molecular-Pharmacology/" rel="tag"><i class="fa fa-tag"></i> Molecular Pharmacology</a>
          </div>

        


        
    <div class="post-nav">
      <div class="post-nav-item">
    <a href="/posts/ad950dfa.html" rel="prev" title="L8 Synaptic transmission">
      <i class="fa fa-chevron-left"></i> L8 Synaptic transmission
    </a></div>
      <div class="post-nav-item">
    <a href="/posts/c0f88b48.html" rel="next" title="L12 Anesthetics (General and local)">
      L12 Anesthetics (General and local) <i class="fa fa-chevron-right"></i>
    </a></div>
    </div>
      </footer>
    
  </article>
  
  
  



          </div>
          
    <div class="comments" id="valine-comments"></div>

<script>
  window.addEventListener('tabs:register', () => {
    let { activeClass } = CONFIG.comments;
    if (CONFIG.comments.storage) {
      activeClass = localStorage.getItem('comments_active') || activeClass;
    }
    if (activeClass) {
      let activeTab = document.querySelector(`a[href="#comment-${activeClass}"]`);
      if (activeTab) {
        activeTab.click();
      }
    }
  });
  if (CONFIG.comments.storage) {
    window.addEventListener('tabs:click', event => {
      if (!event.target.matches('.tabs-comment .tab-content .tab-pane')) return;
      let commentClass = event.target.classList[1];
      localStorage.setItem('comments_active', commentClass);
    });
  }
</script>

        </div>
          
  
  <div class="toggle sidebar-toggle">
    <span class="toggle-line toggle-line-first"></span>
    <span class="toggle-line toggle-line-middle"></span>
    <span class="toggle-line toggle-line-last"></span>
  </div>

  <aside class="sidebar">
    <div class="sidebar-inner">

      <ul class="sidebar-nav motion-element">
        <li class="sidebar-nav-toc">
          文章目录
        </li>
        <li class="sidebar-nav-overview">
          站点概览
        </li>
      </ul>

      <!--noindex-->
      <div class="post-toc-wrap sidebar-panel">
          <div class="post-toc motion-element"><ol class="nav"><li class="nav-item nav-level-1"><a class="nav-link" href="#%E4%B8%80-introduction"><span class="nav-text"> 一、Introduction</span></a><ol class="nav-child"><li class="nav-item nav-level-2"><a class="nav-link" href="#nature-of-epilepsy"><span class="nav-text"> Nature of Epilepsy</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#types-of-epilepsy"><span class="nav-text"> Types of Epilepsy</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#seizure-classification"><span class="nav-text"> Seizure Classification</span></a></li></ol></li><li class="nav-item nav-level-1"><a class="nav-link" href="#%E4%BA%8C-basic-pharmacology-of-antiseizure-drugs"><span class="nav-text"> 二、Basic Pharmacology of Antiseizure Drugs</span></a><ol class="nav-child"><li class="nav-item nav-level-2"><a class="nav-link" href="#drug-mechanisms"><span class="nav-text"> Drug mechanisms</span></a></li><li class="nav-item nav-level-2"><a class="nav-link" href="#drugs-used-in-partial-seizures-generalized-tonic-clonic-seizures"><span class="nav-text"> Drugs Used in Partial Seizures &amp; Generalized Tonic-Clonic Seizures</span></a></li></ol></li><li class="nav-item nav-level-1"><a class="nav-link" href="#%E4%B8%89-degenerative-diseases-of-the-nervous-system"><span class="nav-text"> 三、Degenerative Diseases of the Nervous System</span></a><ol class="nav-child"><li class="nav-item nav-level-2"><a class="nav-link" href="#parkinsons-disease"><span class="nav-text"> Parkinson’s disease</span></a></li></ol></li></ol></div>
      </div>
      <!--/noindex-->

      <div class="site-overview-wrap sidebar-panel">
        <div class="site-author motion-element" itemprop="author" itemscope itemtype="http://schema.org/Person">
    <img class="site-author-image" itemprop="image" alt="向海"
      src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/next/pixil-frame-0.png">
  <p class="site-author-name" itemprop="name">向海</p>
  <div class="site-description" itemprop="description">希望能活的久一点</div>
</div>
<div class="site-state-wrap motion-element">
  <nav class="site-state">
      <div class="site-state-item site-state-posts">
          <a href="/archives/">
        
          <span class="site-state-item-count">187</span>
          <span class="site-state-item-name">日志</span>
        </a>
      </div>
      <div class="site-state-item site-state-categories">
            <a href="/categories/">
          
        <span class="site-state-item-count">23</span>
        <span class="site-state-item-name">分类</span></a>
      </div>
      <div class="site-state-item site-state-tags">
            <a href="/tags/">
          
        <span class="site-state-item-count">23</span>
        <span class="site-state-item-name">标签</span></a>
      </div>
  </nav>
</div>
  <div class="links-of-author motion-element">
      <span class="links-of-author-item">
        <a href="mailto:zhenyumi@foxmail.com" title="E-Mail → mailto:zhenyumi@foxmail.com" rel="noopener" target="_blank"><i class="fa fa-envelope fa-fw"></i>E-Mail</a>
      </span>
      <span class="links-of-author-item">
        <a href="https://weibo.com/u/2279880515" title="Weibo → https:&#x2F;&#x2F;weibo.com&#x2F;u&#x2F;2279880515" rel="noopener" target="_blank"><i class="fab fa-weibo fa-fw"></i>Weibo</a>
      </span>
      <span class="links-of-author-item">
        <a href="https://twitter.com/ParaDogs_lazy" title="Twitter → https:&#x2F;&#x2F;twitter.com&#x2F;ParaDogs_lazy" rel="noopener" target="_blank"><i class="fab fa-twitter fa-fw"></i>Twitter</a>
      </span>
      <span class="links-of-author-item">
        <a href="https://t.me/Furemu" title="Telegram → https:&#x2F;&#x2F;t.me&#x2F;Furemu" rel="noopener" target="_blank"><i class="fab fa-telegram fa-fw"></i>Telegram</a>
      </span>
  </div>


<!-- none-select-br -->

<p></p>

<!-- hitokoto -->

<div class="hitokoto-title">
	<i class="fa fa-paragraph"></i>
	<b>一言</b>
</div>

<div id="hitokoto">获取中OvO</div>
<i id="hitofrom">获取中OvO</i>

<script src="https://cdn.jsdelivr.net/npm/bluebird@3/js/browser/bluebird.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/whatwg-fetch@2.0.3/fetch.min.js"></script>
<script>
  fetch('https://v1.hitokoto.cn/?c=i')
    .then(function (res){
      return res.json();
    })
    .then(function (data) {
      var hitokoto = document.getElementById('hitokoto');
      hitokoto.innerText = '\xa0\xa0\xa0\xa0\xa0\xa0\xa0' + data.hitokoto;
      var hitofrom = document.getElementById('hitofrom');
      hitofrom.innerText = "——" + data.from + '\xa0'; 
    })
    .catch(function (err) {
      console.error(err);
    })
</script>
      </div>

    </div>
  </aside>
  <div id="sidebar-dimmer"></div>


      </div>
    </main>

    <footer class="footer">
      <div class="footer-inner">
        

        

<div class="copyright">
  
  &copy; 2020 – 
  <span itemprop="copyrightYear">2021</span>
  <span class="with-love">
    <i class="fa fa-heart"></i>
  </span>
  <span class="author" itemprop="copyrightHolder">向海</span>
    <span class="post-meta-divider">|</span>
    <span class="post-meta-item-icon">
      <i class="fa fa-chart-area"></i>
    </span>
      <span class="post-meta-item-text">站点总字数：</span>
    <span title="站点总字数">2.8m</span>
    <span class="post-meta-divider">|</span>
    <span class="post-meta-item-icon">
      <i class="fa fa-coffee"></i>
    </span>
      <span class="post-meta-item-text">站点阅读时长 &asymp;</span>
    <span title="站点阅读时长">42:18</span>
</div><br /> <!-- 换行 -->

<div class="translate-style">
繁/简：<a id="translateLink" href="javascript:translatePage();">繁体
</a>
</div>
<script type="text/javascript" src="/js/tw_cn.js"></script>
<script type="text/javascript">
var defaultEncoding = 2; //网站编写字体是否繁体，1-繁体，2-简体
var translateDelay = 0; //延迟时间,若不在前, 要设定延迟翻译时间, 如100表示100ms,默认为0
var cookieDomain = "https://tding.top/"; //Cookie地址, 一定要设定, 通常为你的网址
var msgToTraditionalChinese = "繁体"; //此处可以更改为你想要显示的文字
var msgToSimplifiedChinese = "简体"; //同上，但两处均不建议更改
var translateButtonId = "translateLink"; //默认互换id
translateInitilization();
</script>

<!-- 网站运行时间的设置 -->
<span id="timeDate">载入天数...</span>
<span id="times">载入时分秒...</span>
<script>
    var now = new Date();
    function createtime() {
        var grt= new Date("06/01/2020 12:00:00");//此处修改你的建站时间或者网站上线时间
        now.setTime(now.getTime()+250);
        days = (now - grt ) / 1000 / 60 / 60 / 24; dnum = Math.floor(days);
        hours = (now - grt ) / 1000 / 60 / 60 - (24 * dnum); hnum = Math.floor(hours);
        if(String(hnum).length ==1 ){hnum = "0" + hnum;} minutes = (now - grt ) / 1000 /60 - (24 * 60 * dnum) - (60 * hnum);
        mnum = Math.floor(minutes); if(String(mnum).length ==1 ){mnum = "0" + mnum;}
        seconds = (now - grt ) / 1000 - (24 * 60 * 60 * dnum) - (60 * 60 * hnum) - (60 * mnum);
        snum = Math.round(seconds); if(String(snum).length ==1 ){snum = "0" + snum;}
        document.getElementById("timeDate").innerHTML = "已正常运行 "+dnum+" 天";
        document.getElementById("times").innerHTML = hnum + " 小时 " + mnum + " 分 " + snum + " 秒 OvO";
    }
setInterval("createtime()",250);
</script>

<br /> <!-- 换行 -->

<!--busuanzi计数-->

    <script async src="//dn-lbstatics.qbox.me/busuanzi/2.3/busuanzi.pure.mini.js"></script>

    <span id="busuanzi_container_site_pv">总访问量<span id="busuanzi_value_site_pv"></span>次</span>
    <span class="post-meta-divider">|</span>
    <span id="busuanzi_container_site_uv">总访客数<span id="busuanzi_value_site_uv"></span>人</span>
    <span class="post-meta-divider">|</span>
<!-- 不蒜子计数初始值纠正 -->
<script>
$(document).ready(function() {

    var int = setInterval(fixCount, 50);  // 50ms周期检测函数
    var countOffset = 20000;  // 初始化首次数据

    function fixCount() {            
       if (document.getElementById("busuanzi_container_site_pv").style.display != "none")
        {
            $("#busuanzi_value_site_pv").html(parseInt($("#busuanzi_value_site_pv").html()) + countOffset); 
            clearInterval(int);
        }                  
        if ($("#busuanzi_container_site_pv").css("display") != "none")
        {
            $("#busuanzi_value_site_uv").html(parseInt($("#busuanzi_value_site_uv").html()) + countOffset); // 加上初始数据 
            clearInterval(int); // 停止检测
        }  
    }
       	
});
</script> 



        
<div class="busuanzi-count">
  <script data-pjax async src="https://busuanzi.ibruce.info/busuanzi/2.3/busuanzi.pure.mini.js"></script>
    <span class="post-meta-item" id="busuanzi_container_site_pv" style="display: none;">
      <span class="post-meta-item-icon">
        <i class="fa fa-eye"></i>
      </span>
      <span class="site-pv" title="总访问量">
        <span id="busuanzi_value_site_pv"></span>
      </span>
    </span>
</div>








      </div>
    </footer>
  </div>

  
  <script src="/lib/anime.min.js"></script>
  <script src="//cdn.jsdelivr.net/gh/theme-next/theme-next-pjax@0/pjax.min.js"></script>
  <script src="//cdn.jsdelivr.net/npm/jquery@3/dist/jquery.min.js"></script>
  <script src="//cdn.jsdelivr.net/gh/fancyapps/fancybox@3/dist/jquery.fancybox.min.js"></script>
  <script src="//cdn.jsdelivr.net/npm/lozad@1/dist/lozad.min.js"></script>
  <script src="//cdn.jsdelivr.net/npm/pangu@4/dist/browser/pangu.min.js"></script>
  <script src="/lib/velocity/velocity.min.js"></script>
  <script src="/lib/velocity/velocity.ui.min.js"></script>

<script src="/js/utils.js"></script>

<script src="/js/motion.js"></script>


<script src="/js/schemes/pisces.js"></script>


<script src="/js/next-boot.js"></script>

<script src="/js/bookmark.js"></script>

  <script>
var pjax = new Pjax({
  selectors: [
    'head title',
    '#page-configurations',
    '.content-wrap',
    '.post-toc-wrap',
    '.languages',
    '#pjax'
  ],
  switches: {
    '.post-toc-wrap': Pjax.switches.innerHTML
  },
  analytics: false,
  cacheBust: false,
  scrollTo : !CONFIG.bookmark.enable
});

window.addEventListener('pjax:success', () => {
  document.querySelectorAll('script[data-pjax], script#page-configurations, #pjax script').forEach(element => {
    var code = element.text || element.textContent || element.innerHTML || '';
    var parent = element.parentNode;
    parent.removeChild(element);
    var script = document.createElement('script');
    if (element.id) {
      script.id = element.id;
    }
    if (element.className) {
      script.className = element.className;
    }
    if (element.type) {
      script.type = element.type;
    }
    if (element.src) {
      script.src = element.src;
      // Force synchronous loading of peripheral JS.
      script.async = false;
    }
    if (element.dataset.pjax !== undefined) {
      script.dataset.pjax = '';
    }
    if (code !== '') {
      script.appendChild(document.createTextNode(code));
    }
    parent.appendChild(script);
  });
  NexT.boot.refresh();
  // Define Motion Sequence & Bootstrap Motion.
  if (CONFIG.motion.enable) {
    NexT.motion.integrator
      .init()
      .add(NexT.motion.middleWares.subMenu)
      .add(NexT.motion.middleWares.postList)
      .bootstrap();
  }
  NexT.utils.updateSidebarPosition();
});
</script>




  




  
<script src="/js/local-search.js"></script>









<script data-pjax>
document.querySelectorAll('.pdfobject-container').forEach(element => {
  let url = element.dataset.target;
  let pdfOpenParams = {
    navpanes : 0,
    toolbar  : 0,
    statusbar: 0,
    pagemode : 'thumbs',
    view     : 'FitH'
  };
  let pdfOpenFragment = '#' + Object.entries(pdfOpenParams).map(([key, value]) => `${key}=${encodeURIComponent(value)}`).join('&');
  let fullURL = `/lib/pdf/web/viewer.html?file=${encodeURIComponent(url)}${pdfOpenFragment}`;

  if (NexT.utils.supportsPDFs()) {
    element.innerHTML = `<embed class="pdfobject" src="${url + pdfOpenFragment}" type="application/pdf" style="height: ${element.dataset.height};">`;
  } else {
    element.innerHTML = `<iframe src="${fullURL}" style="height: ${element.dataset.height};" frameborder="0"></iframe>`;
  }
});
</script>


<script data-pjax>
if (document.querySelectorAll('pre.mermaid').length) {
  NexT.utils.getScript('//cdn.jsdelivr.net/npm/mermaid@8/dist/mermaid.min.js', () => {
    mermaid.initialize({
      theme    : 'forest',
      logLevel : 3,
      flowchart: { curve     : 'linear' },
      gantt    : { axisFormat: '%m/%d/%Y' },
      sequence : { actorMargin: 50 }
    });
  }, window.mermaid);
}
</script>


    <div id="pjax">
  

  
      
<link rel="stylesheet" href="//cdn.jsdelivr.net/npm/katex@0/dist/katex.min.css">
  <script src="//cdn.jsdelivr.net/npm/katex@0/dist/contrib/copy-tex.min.js"></script>
  <link rel="stylesheet" href="//cdn.jsdelivr.net/npm/katex@0/dist/contrib/copy-tex.min.css">


  
  <script src="//cdn.jsdelivr.net/npm/quicklink@1/dist/quicklink.umd.js"></script>
  <script>
      window.addEventListener('load', () => {
      quicklink({
        timeout : 3000,
        priority: true,
        ignores : [uri => uri.includes('#'),uri => uri === 'https://zhenyumi.github.io/posts/bdf8ab92.html',]
      });
      });
  </script>


<script>
NexT.utils.loadComments(document.querySelector('#valine-comments'), () => {
  NexT.utils.getScript('//cdn.jsdelivr.net/npm/valine@1/dist/Valine.min.js', () => {
    var GUEST = ['nick', 'mail', 'link'];
    var guest = 'nick,mail,link';
    guest = guest.split(',').filter(item => {
      return GUEST.includes(item);
    });
    new Valine({
      el         : '#valine-comments',
      verify     : false,
      notify     : true,
      appId      : 'ErV27FWAFsY2HDPhLVjeIcfR-MdYXbMMI',
      appKey     : 'YyUrjqWLM53k8C1tPcKNaQFN',
      placeholder: "Leave Something?",
      avatar     : 'mm',
      meta       : guest,
      pageSize   : '10' || 10,
      visitor    : false,
      lang       : 'zh-ch' || 'zh-cn',
      path       : location.pathname,
      recordIP   : true,
      serverURLs : ''
    });
  }, window.Valine);
});
</script>

    </div>
</body>
</html>
